Trends in liver transplantation for autoimmune liver diseases: a Canadian study
暂无分享,去创建一个
G. Hirschfield | N. Selzner | G. Sapisochin | T. Ivanics | P. Yoon | M. Claasen | D. Wallace | B. Hansen | C. F. Murillo Perez
[1] K. Zieniewicz,et al. Characteristics, Trends, and Outcomes of Liver Transplantation for Primary Sclerosing Cholangitis in Female Versus Male Patients: An Analysis From the European Liver Transplant Registry , 2020, Transplantation.
[2] F. Carrat,et al. Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. , 2020, Journal of hepatology.
[3] K. Zieniewicz,et al. Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry , 2020, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[4] A. Bonder,et al. Increased Posttransplant Mortality for Autoimmune Hepatitis Compared With Other Autoimmune Liver Diseases , 2019, Journal of clinical gastroenterology.
[5] K. Kang,et al. Allocation of Liver Grafts Worldwide Is there a best System? , 2019, Journal of hepatology.
[6] N. Kneteman,et al. Canadian liver transplant allocation for hepatocellular carcinoma. , 2019, Journal of hepatology.
[7] F. Nevens,et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. , 2019, Journal of hepatology.
[8] V. Wong,et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[9] K. Zieniewicz,et al. Trends in liver transplantation for primary biliary cholangitis in Europe over the past three decades , 2018, Alimentary pharmacology & therapeutics.
[10] Amélie Quesnel-Vallée,et al. Canada's universal health-care system: achieving its potential , 2018, The Lancet.
[11] C. Bowlus,et al. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update , 2016, Journal of managed care & specialty pharmacy.
[12] J. Reguła,et al. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. , 2016, The New England journal of medicine.
[13] A. Burroughs,et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. , 2014, Gastroenterology.
[14] D. Raptis,et al. The model for end‐stage liver disease allocation system for liver transplantation saves lives, but increases morbidity and cost: a prospective outcome analysis , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[15] S. Friedman,et al. Transplantation trends in primary biliary cirrhosis. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[16] P. Kamath,et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts , 2000, Hepatology.